8% capsaicin patches for HIV-induced polyneuropathy: a systematic review and meta-analysis.

Pain ManagJun 3, 2026 (epub)
Clinical ResearchInfectious DiseasesNeurology

Brandon J Goodwin, Ankur Jain, Jessica Mitchell et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy of 8% capsaicin patches for treating HIV-induced polyneuropathy. Analyzing seven studies, the review found a significant improvement in pain scores, with an overall effect size of d = 0.991 (95% CI: 0.619-1.36). The findings suggest that capsaicin patches may be beneficial for this patient population.

Key findings

  • Overall effect size for pain score improvement was d = 0.991 (95% CI: 0.619-1.36).
  • Leave-out analysis showed a repeat effect size of d = 0.96 after excluding high-risk bias studies.
  • Seven articles met the inclusion criteria for the systematic review.

Why it matters

HIV-induced neuropathy presents significant treatment challenges due to the side effects of standard medications. This review highlights a potential alternative therapy that may improve patient outcomes and quality of life.

Source

PubMed · PMID 42237588

Published in Pain Manag. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.